Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial ...
Cabaletta Bio (CABA) remains a Buy: rese-cel trial catalysts, autoimmune upside, scalable manufacturing, and key risks like ...
1d
Hyosung TNC Marks a Major Step in its Integrated Bio-Spandex Platform at Global Fashion Summit 2026
COPENHAGEN, Denmark and SEOUL, South Korea, May 13, 2026 /PRNewswire/ -- Hyosung TNC, a complete sustainable textile solutions provider and the largest manufacturer of spandex (elastane) by ...
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 ...
Bank of America Global Healthcare Conference 2026 May 13, 2026 11:00 AM EDTCompany ParticipantsDavid Hung - Founder, President, ...
The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...
Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label ...
The ustekinumab biosimilar AVT04 has consistent efficacy through 28 weeks in patients with PsO with and without prior ustekinumab exposure.
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV Hondius is consistent with a spillover from ...
New York’s Finest is wants to take a bite out of the city’s police watchdog. The supervisor of the investigators who probe ...
Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results